|Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.||Co-Founder & Exec. Chairman||714.25k||N/A||1949|
|Dr. David D. Chang M.D., Ph.D.||Co-Founder, Pres, CEO & Director||1.1M||N/A||1960|
|Mr. Joshua A. Kazam||Co-Founder & Director||711k||N/A||1977|
|Yinlin Chen||Sr. VP of Fin.||N/A||N/A||N/A|
|Mr. Timothy L. Moore Ph.D.||Exec. VP & Chief Technical Officer||N/A||N/A||1961|
|Mr. Earl M. Douglas Esq.||Gen. Counsel & Compliance Officer||N/A||N/A||1963|
|Ms. Susan R. Lundeen||Chief People Officer||N/A||N/A||1966|
|Ms. Christine Cassiano||Exec. VP, Chief Corp. Affairs & Brand Strategy Officer||N/A||N/A||N/A|
|Dr. Zachary J. Roberts M.D., Ph.D.||Exec. VP of R&D and Chief Medical Officer||N/A||N/A||1978|
|Mr. David M. Tanen J.D.||Sec.||N/A||N/A||1971|
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Allogene Therapeutics, Inc.’s ISS governance QualityScore as of 1 October 2023 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 8; Compensation: 10.